Oxytocin and Cognitive Control in Adult ADHD

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

November 5, 2020

Study Completion Date

November 5, 2020

Conditions

Attention Deficit/Hyperactivity Disorder

Interventions

DRUG

Oxytocin nasal spray

Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)

DRUG

Placebo nasal spray

Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)

Trial Locations (1)

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER

NCT03136263 - Oxytocin and Cognitive Control in Adult ADHD | Biotech Hunter | Biotech Hunter